BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21709400)

  • 1. Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
    Ide H; Satou A; Hoshino K; Yasumizu Y; Uchida Y; Tasaka Y; Masuda T
    Urol Int; 2011; 87(2):245-7. PubMed ID: 21709400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
    Kojima Y; Takahi Y; Ichimaru N; Okumi M; Takahara S; Nonomura N
    BMC Res Notes; 2015 Feb; 8():25. PubMed ID: 25648269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
    Kobayashi Y; Nishimura K; Soda T; Yamanaka K; Hirai T; Kishikawa H; Ichikawa Y
    Hinyokika Kiyo; 2010 Jan; 56(1):29-34. PubMed ID: 20104007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
    Terakawa T; Miyake H; Yokoyama N; Miyazaki A; Tanaka H; Inoue T; Fujisawa M
    Urol Int; 2014; 92(2):180-5. PubMed ID: 24246751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
    Suyama T; Ueda T; Fukasawa S; Imamura Y; Nakamura K; Miyasaka K; Sazuka T; Egoshi K; Nihei N; Hamano M; Ichikawa T; Maruoka M
    Jpn J Clin Oncol; 2009 Apr; 39(4):244-50. PubMed ID: 19211575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
    Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
    Grivas PD; Hussain M; Hafez K; Daignault-Newton S; Wood D; Lee CT; Weizer A; Montie JE; Hollenbeck B; Montgomery JS; Alva A; Smith DC
    Urology; 2013 Jul; 82(1):111-7. PubMed ID: 23706253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
    Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
    Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
    Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
    Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
    Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
    Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
    Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
    J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
    Hahn NM; Stadler WM; Zon RT; Waterhouse D; Picus J; Nattam S; Johnson CS; Perkins SM; Waddell MJ; Sweeney CJ;
    J Clin Oncol; 2011 Apr; 29(12):1525-30. PubMed ID: 21422406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
    Song Y; Yang L; Zhou A; Chi Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Hainsworth JD; Meluch AA; Litchy S; Schnell FM; Bearden JD; Yost K; Greco FA
    Cancer; 2005 Jun; 103(11):2298-303. PubMed ID: 15856431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
    Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.